New treatments developed by ASU researchers are brightening the outlook for treating people with autism and children with the rare disorder called Pitt-Hopkins syndrome. It’s the result of decades of work to find such treatments. Progress has been aided by the work of Fulton Schools Professors James Adams and Rosa Krajmalnik-Brown. Adams, director of ASU’s Autism/Asperger’s Research Program, and Brown, director of the Biodesign Center for Health Through Microbiomes, first hypothesized that microbiotic transplant therapy could improve the conditions of people with autism. Such microbiome treatments are now among the more promising of the advances raising hopes of better treatments for health disorders that cause physical, mental and developmental problems.